Literature DB >> 17336975

Investigation of hypothalamo-pituitary-gonadal axis and glucose intolerance among the first-degree female relatives of women with polycystic ovary syndrome.

Kürşad Unlühizarci1, Mehtap Ozocak, Fatih Tanriverdi, Hulusi Atmaca, Fahrettin Keleştimur.   

Abstract

OBJECTIVE: To assess the glucose intolerance and the hypothalamo-pituitary-gonadal (HPG) axis in the first-degree relatives (FDRs) of patients with polycystic ovary syndrome (PCOS).
DESIGN: Clinical study of the female FDRs of patients with PCOS.
SETTING: Outpatients at endocrinology department of a university hospital. PATIENT(S): Seventy FDRs of PCOS patients and 20 healthy women were evaluated. INTERVENTION(S): Basal hormonal investigations, buserelin test, and 75-g oral glucose tolerance test (OGTT) were performed. MAIN OUTCOME MEASURE(S): Basal hormone levels were measured. Additionally, insulinogenic index, glucose and insulin responses to OGTT, and FSH, LH, E(2), and 17-OHP responses to buserelin test were obtained. RESULT(S): Four (5.7%) of the FDRs showed impaired glucose tolerance, and the FDRs had significantly higher fasting plasma glucose (P<.05) and basal insulin (P<.01) than control subjects. Peak and area-under-the-curve (AUC) insulin (P<.001) and AUC glucose (P<.05) responses to OGTT were also significantly higher in the FDRs than in control subjects. The FDRs showed higher insulinogenic index than the control subjects (P<.001). The FDRs had significantly (P<.05) higher LH and DHEAS levels and lower (P<.005) 17-OHP levels than the control subjects. Peak (P<.05) and AUC (P<.01) LH responses to buserelin testing were lower in the FDRs than in the control subjects while peak (P<.05) and AUC (P<.01) E(2) responses to buserelin were higher in the FDRs than in the control subjects. CONCLUSION(S): These data support the hypothesis that FDRs of PCOS patients may have insulin resistance and the HPG axis is more susceptible than in control subjects. The FDRs also have an increased prevalence of hyperandrogenism and high DHEAS levels compared with the background population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336975     DOI: 10.1016/j.fertnstert.2006.11.075

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

1.  Profile of Daughters and Sisters of Women With Polycystic Ovary Syndrome: The Role of Proband's Glucose Tolerance.

Authors:  Soren Harnois-Leblanc; Maria Isabel Hernandez; Ethel Codner; Fernando Cassorla; Sharon E Oberfield; Natasha I Leibel; Revi P Mathew; Svetlana Ten; Denis A Magoffin; Christianne J Lane; Michael I Goran; Ricardo Azziz; Jean-Patrice Baillargeon; David H Geller
Journal:  J Clin Endocrinol Metab       Date:  2022-02-17       Impact factor: 5.958

Review 2.  Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Bulent Yilmaz; Priyathama Vellanki; Baris Ata; Bulent Okan Yildiz
Journal:  Fertil Steril       Date:  2018-01-11       Impact factor: 7.329

3.  Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome.

Authors:  Nouhad Raissouni; Andrey Kolesnikov; Radhika Purushothaman; Sunil Sinha; Sonal Bhandari; Amrit Bhangoo; Shahid Malik; Revi Mathew; Jean-Patrice Baillargeon; Maria Isabel Hernandez; Michael Rosenbaum; Svetlana Ten; David Geller
Journal:  Int J Pediatr Endocrinol       Date:  2012-05-29

Review 4.  Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.

Authors:  H Teede; A Deeks; L Moran
Journal:  BMC Med       Date:  2010-06-30       Impact factor: 8.775

5.  Evolution of metabolic alterations 5 Years after early puberty in a cohort of girls predisposed to polycystic ovary syndrome.

Authors:  Soren Harnois-Leblanc; Andréanne Trottier; Samuel Leblanc; Marie-Claude Battista; David H Geller; Jean-Patrice Baillargeon
Journal:  Reprod Biol Endocrinol       Date:  2017-07-24       Impact factor: 5.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.